Overview

Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
To evaluate activity of gefitinib in subjects with relapsed prostate cancer by estimating PSA response rate at study closure
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gefitinib